Visit Sclero Forums, Chats and Blogs!
 
Search sclero.org:
 
The most important thing in the world to know about
scleroderma is sclero.org with 5,000+ pages in 23 languages!
 
Donate in MemoryIn loving memory of Tom Regensburger, and Vera Kortan . (Donate)
Home   Medical   News   *Sclero Forums*   Support   Languages/Countries
Earn $150 on July 30th in Boston Marketing Research Study if you have scleroderma or CTD and have been screened for pulmonary hypertension!
Frog jumping for joy by Shelley EnszPDF Flyer: Boston Marketing Research Study. Schlesinger Associates-Boston, a national marketing research company, is currently looking for patients who have been diagnosed with Scleroderma or other Connective Tissue Disease, who either have pulmonary hypertension or who are regularly screened for it, to participate in a July 30th paid marketing research study in Boston. Read PDF Flyer: Boston Marketing Research Study or call Katherine at 617-542-5500 x310. Schlesinger Associates-Boston. Posted 07/26/10.
Scleroderma Newsroom
Janey WillisHello, I am Janey Willis, ISN News Director and ISN Asst. Webmaster. David Becker, ISN Assistant News Guide researches our Autoimmune News section. Jeannie McClelland, ISN Assistant News Guide, researches Scleroderma Medical and Media News. Assistant News Guide Lisa Bulman posts these stories to our Sclero Forums.
Scleroderma Medical News
Autoimmune News
Media Stories
New Personal Stories
ISN Website & Donation News

Autoimmune Medical News by Date

December 2009
Effect of Pilates Training on People With Fibromyalgia Syndrome (FMS): A Pilot Study. We suggest Pilates as an effective and safe method for people with FMS. We believe that further research with more participants and longer follow-up periods could help assess the therapeutic value of this popular physical exercise method. L. Altan, MD. Archives of Physical Medicine and Rehabilitation. Vol 90, Issue 12, Pp 1983-1988. December 2009. (Also see: Treatments of FMS)
Fibromyalgia (FM): The diagnosis and pharmacologic treatment. Recently, three drugs: pregabalin, duloxetine and milnacipran have been approved by the Food and Drug Administration (FDA) for treatment of FM. D. Buskila. European Journal of Pain. November 2009. (Also see: Treatments of FMS)
Role and place of methotrexate in vasculitis management. Methotrexate is a folic acid analog with a favorable efficacy-to-toxicity ratio that has been used for many years to treat a variety of inflammatory arthropathies, thereby explaining the growing interest in its use for systemic vasculitides. However, it should be prescribed with caution or avoided in vasculitis patients with impaired renal function. (FutureMedicine) C. Pagnoux. International Journal of Clinical Rheumatology. December 2009. (Also see: Vasculitis and Medications)
Autologous hematopoietic stem cell transplantation (HSCT) in autoimmune diseases. Growing experience with autologous HCST in autoimmune diseases has progressively reduced concerns about transplant-related mortality and secondary myelodysplasia/leukemia. Therefore, a sustained complete remission seems to be within the reach of autografting in some autoimmune diseases; in others, the indications, risks and benefits of autografting need to be better defined. C. Annaloro. Expert Review of Hematology. December 2009. (Also see: Treating Autoimmunity)
The relationship between race, cigarette smoking and carotid intimal medial thickness (mIMT) in systemic lupus erythematosus (SLE). Black women, but not White, with SLE with a history of smoking have higher mIMT measurements than those who have never smoked. This is the first report documenting the race-specific effect of smoking on subclinical measures of cardiovascular disease in SLE. (SageJournals) LV Scalzi. Lupus. December 1 2009. (Also see: Lupus and Heart Disease)
The immunoregulatory role of vitamins A, D and E in patients with primary Sjögren’s syndrome (pSS). Our data suggest that fat-soluble vitamins may be important in immunoregulatory processes in patients with pSS. P. Szodoray. Rheumatology Advance Access. November 27 2009. (Also see: Sjögren's)
 
Go to Autoimmune News: November 2009
 
SCLERO.ORG is brought to you by the nonprofit International Scleroderma Network (ISN). The ISN is a full-service nonprofit scleroderma charitable foundation providing stellar research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension.
  1. Post a message in Sclero Forums
  2. Email: isn@sclero.org
  3. English Email Form
  4. Español Email Form
  5. Italiano Email Form
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702
United States

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information: verify here.

Toll Free Hotline in U.S.
Hours: 9am-3pm CST only.
Please leave a complete message, in English.
1-800-564-7099
Direct Line
1-952-583-5735
We are also known as the Scleroderma from A to Z web site.
Privacy Policy, Financial Disclosure, and Disclaimer.
© Copyright 1998-2010 International Scleroderma Network
All Rights Reserved
 
Home   Donate   Medical   News   *Sclero Forums*   Support   Translations   Search